Thomas Sciascia Biography and Net Worth

Co-Founder, Chief Scientific Officer of Trevi Therapeutics

Thomas Sciascia, M.D., is our co-founder and has served as our Chief Scientific Officer since November 2022. Prior to that, he served as our Chief Medical Officer from our inception, in March 2011, until November 2022. Previously, Dr. Sciascia was the Senior Vice President of Clinical Development and Regulatory and Chief Medical Officer at Penwest from 2001 to 2010. Prior to joining Penwest, Dr. Sciascia worked at Quintiles, Inc. from 1997 to 2000 as a consultant to pharmaceutical and biotechnology companies. Dr. Sciascia also worked as Medical Director at Transkaryotic Therapies, Inc. (later acquired by Shire Pharmaceuticals Group plc) from 2000 to 2001. Dr. Sciascia received a B.S. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. He is a board-certified neurologist licensed to practice medicine in the state of Massachusetts.

What is Thomas Sciascia's net worth?: The estimated net worth of Thomas Sciascia is at least $2.97 million as of August 16th, 2024. Dr. Sciascia owns 220,315 shares of Trevi Therapeutics stock worth more than $2,967,643 as of December 5th. This net worth evaluation does not reflect any other assets that Dr. Sciascia may own. Additionally, Dr. Sciascia receives a salary of $530,480.00 as Co-Founder, Chief Scientific Officer at Trevi Therapeutics. Learn More about Thomas Sciascia's net worth.
How old is Thomas Sciascia?: Dr. Sciascia is currently 71 years old. There are 5 older executives and no younger executives at Trevi Therapeutics. Learn More on Thomas Sciascia's age.
What is Thomas Sciascia's salary?: As the Co-Founder, Chief Scientific Officer of Trevi Therapeutics, Inc., Dr. Sciascia earns $530,480.00 per year. The highest earning executive at Trevi Therapeutics is Ms. Jennifer L. Good, Co-Founder, CEO, President & Director, who commands a salary of $781,850.00 per year. Learn More on Thomas Sciascia's salary.
How do I contact Thomas Sciascia?: The corporate mailing address for Dr. Sciascia and other Trevi Therapeutics executives is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. Trevi Therapeutics can also be reached via phone at (203) 304-2499 and via email at [email protected]. Learn More on Thomas Sciascia's contact information.
Has Thomas Sciascia been buying or selling shares of Trevi Therapeutics?: Thomas Sciascia has not been actively trading shares of Trevi Therapeutics during the past quarter. Most recently, Thomas Sciascia sold 18,660 shares of the business's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $2.76, for a transaction totalling $51,501.60. Following the completion of the sale, the insider now directly owns 220,315 shares of the company's stock, valued at $608,069.40. Learn More on Thomas Sciascia's trading history.
Who are Trevi Therapeutics' active insiders?: Trevi Therapeutics' insider roster includes Lisa Delfini (CFO), Jennifer Good (Co-Founder, President and CEO), David Meeker (Director), Thomas Sciascia (Co-Founder, Chief Scientific Officer), and Farrell Simon (Insider). Learn More on Trevi Therapeutics' active insiders.
Are insiders buying or selling shares of Trevi Therapeutics?: In the last year, insiders at the sold shares 2 times. They sold a total of 86,576 shares worth more than $583,493.29. The most recent insider tranaction occured on March, 21st when CEO Jennifer L Good sold 5,263 shares worth more than $34,630.54. Insiders at Trevi Therapeutics own 18.3% of the company. Learn More about insider trades at Trevi Therapeutics.
Information on this page was last updated on 3/21/2025.

Thomas Sciascia Insider Trading History at Trevi Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/16/2024	Sell	18,660	$2.76	$51,501.60	220,315
8/14/2024	Sell	100	$2.75	$275.00	220,315
5/29/2024	Sell	53,368	$2.55	$136,088.40	214,433

Thomas Sciascia Buying and Selling Activity at Trevi Therapeutics

Trevi Therapeutics Company Overview

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $13.47

$13.35

$14.00

50 Day Range

MA: $10.97

$8.77

$13.70

2 Week Range

Now: $13.47

$2.36

$14.00

Volume

2,803,945 shs

Average Volume

1,989,890 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Thomas Sciascia Biography and Net Worth

What is Thomas Sciascia's net worth?

How old is Thomas Sciascia?

What is Thomas Sciascia's salary?

How do I contact Thomas Sciascia?

Has Thomas Sciascia been buying or selling shares of Trevi Therapeutics?

Who are Trevi Therapeutics' active insiders?

Are insiders buying or selling shares of Trevi Therapeutics?